Latest News and Press Releases

- Collaborative research agreement will utilize Actinium’s AWE Technology Platform to generate Actinium Radio-Conjugates on selected Astellas targeting agents  - Actinium to perform preclinical...

NEW YORK, March 15, 2018 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN:ATNM) ("Actinium" or "the Company"), announced today that it will be attending and presenting at the 28th...

Dr. Rowlands joins Actinium with almost two decades of experience as a regulatory affairs strategist specialized in the development of first-in-class therapeutics for the treatment of rare and/or...

Clinical trial to be conducted by the Medical College of Wisconsin as an investigator initiated trial led by Dr. Sameem Abedin in collaboration with Dr. Ehab Atallah  Combination trial expands...

NEW YORK, March 07, 2018 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN:ATNM) ("Actinium" or "the Company"), announced today that it will be attending and presenting at the 30th...

NEW YORK, March 05, 2018 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc.  (NYSE American:ATNM) ("Actinium" or "the Company") announced today that the Company’s previously announced rights...

-  Protocol changes to the control arm of the pivotal Phase 3 trial for Iomab-B well received at the Company’s investigator meeting and by Iomab-B’s scientific advisory board  -  Product theater...

-  Current clinical trial sites represent over one-third of bone marrow transplant volume in the U.S. -  Actinium expects continued site additions to support enrollment and trial completion...

-  Pricing of the units has been amended to $0.50 per unit with corresponding amendments to the warrant exercise prices -  Timing of the offering is expected to be unchanged and the subscription...

- Subscription period expected to end on March 2, 2018 at 5:00 PM ET NEW YORK, Feb. 22, 2018 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc.  (NYSE American:ATNM) ("Actinium" or "the Company"),...